Pathogenic variants in DPM1 and DPM2 are associated with muscle–eye–brain (MEB) disease, whereas DPM3 variants have mostly been reported in patients with isolated muscle disease—dystroglycanopathy. The gene discussed is DPM3; the disease is neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan.